RxDoctor Payments Data

Thomas Mathew, MD

Cardiovascular Disease · New Hartford, NYNPI 1205820321

Payments from drug & device makers

$13,413in general payments, 2019–2025

Across 362 payments — averaging $37.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Cardiovascular Systems Inc.$1K
  • Novartis$1K
  • Medtronic$870
  • AstraZeneca$520
  • Sanofi-aventis U.S. LLC$484
  • plus $3K from 25 others

What the payments were for

  • Speaking & faculty fees$5,25039%
  • Travel & lodging$1,97315%
  • Food & beverage$6,19046%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,413 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$238,417
Medicare patients
1,627
Services billed
2,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$531,402
EntrestoSacubitril/Valsartan326$451,932
JardianceEmpagliflozin248$314,495
MultaqDronedarone Hcl72$147,526
FarxigaDapagliflozin Propanediol86$99,858
XareltoRivaroxaban57$60,268
Repatha SureclickEvolocumab24$27,750
Repatha SyringeEvolocumab18$23,947
Dabigatran EtexilateDabigatran Etexilate Mesylate60$18,483
BrilintaTicagrelor18$16,437
OzempicSemaglutide13$14,576
Praluent PenAlirocumab11$11,834
Metoprolol Succinate379$7,512
Amiodarone Hcl133$7,021
Propafenone Hcl ErPropafenone Hcl14$6,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,766$531,402391 claims
NovartisEntresto$1,195$451,932326 claims
Boehringer IngelheimJardiance$337$314,495248 claims
Sanofi-aventis U.S. LLCMultaq$484$147,52672 claims
AstraZenecaFarxiga, Brilinta$520$116,296104 claims
Johnson & JohnsonXarelto$99$60,26857 claims
Novo NordiskOzempic$36$14,57613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →